55m
Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ...
Aytu BioPharma Inc (AYTU) surpasses revenue expectations with robust ADHD sales and prepares for the promising launch of Exua amidst strategic realignments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback